Molecular Partners AG (SW:MOLN) — Stock Price

CHF3.27 CHF
▲ 0.93% today

Molecular Partners AG (SW:MOLN) is currently trading at CHF3.27 CHF, up 0.93% today. Over the past 52 weeks, shares have ranged between CHF2.75 and CHF3.95. This page tracks Molecular Partners AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see MOLN stock market capitalisation.

Molecular Partners AG (MOLN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Molecular Partners AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.

Molecular Partners AG Income Statement — Revenue, Profit & Earnings by Year

Molecular Partners AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue CHF4.97 Million CHF7.04 Million CHF189.56 Million CHF9.33 Million CHF9.34 Million
Cost of Revenue CHF47.50 Million CHF47.84 Million CHF50.75 Million CHF55.72 Million CHF56.08 Million
Gross Profit CHF-42.53 Million CHF-40.81 Million CHF138.81 Million CHF-46.39 Million CHF-46.73 Million
Research & Development CHF48.60 Million CHF48.78 Million CHF50.75 Million CHF55.72 Million CHF56.08 Million
SG&A CHF17.16 Million CHF19.00 Million CHF21.82 Million CHF16.91 Million CHF11.03 Million
Total Operating Expenses CHF18.68 Million CHF20.30 Million CHF72.94 Million CHF72.75 Million CHF67.67 Million
Operating Income CHF-61.22 Million CHF-61.11 Million CHF116.61 Million CHF-63.42 Million CHF-58.33 Million
EBITDA CHF-51.63 Million CHF-59.52 Million CHF119.00 Million CHF-60.66 Million CHF-59.58 Million
EBIT CHF-54.00 Million CHF-61.94 Million CHF116.61 Million CHF-63.23 Million CHF-62.47 Million
Interest Expense CHF38.00K CHF49.00K CHF619.00K CHF556.00K CHF304.00K
Income Before Tax CHF-54.04 Million CHF-61.98 Million CHF117.85 Million CHF-63.78 Million CHF-62.77 Million
Income Tax Expense CHF2.00K CHF2.25 Million CHF-717.00K CHF2.00K CHF-11.00K
Net Income CHF-54.04 Million CHF-61.98 Million CHF117.85 Million CHF-63.78 Million CHF-62.76 Million

Molecular Partners AG Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Molecular Partners AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets CHF158.53 Million CHF198.35 Million CHF262.26 Million CHF172.67 Million CHF187.55 Million
Total Current Assets CHF154.28 Million CHF192.46 Million CHF254.75 Million CHF164.19 Million CHF177.81 Million
Cash & Equivalents
Short-term Investments CHF85.56 Million CHF119.58 Million CHF161.20 Million CHF61.00 Million CHF40.00 Million
Net Receivables CHF1.11 Million CHF1.75 Million CHF1.70 Million CHF25.73 Million CHF2.84 Million
Inventory CHF2.00 CHF-199.00K
Property, Plant & Equipment CHF4.20 Million CHF5.68 Million CHF7.24 Million CHF8.15 Million CHF9.39 Million
Goodwill
Total Liabilities CHF16.89 Million CHF21.92 Million CHF27.09 Million CHF65.38 Million CHF80.33 Million
Total Current Liabilities CHF10.79 Million CHF14.42 Million CHF17.25 Million CHF46.87 Million CHF57.67 Million
Long-term Debt
Net Debt CHF-61.43 Million CHF-63.66 Million CHF-83.10 Million CHF-65.77 Million CHF-126.50 Million
Total Stockholder Equity CHF141.64 Million CHF176.43 Million CHF235.17 Million CHF107.29 Million CHF107.22 Million
Retained Earnings CHF-246.29 Million CHF-191.75 Million CHF-127.78 Million CHF-250.95 Million CHF-195.17 Million

Molecular Partners AG Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Molecular Partners AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow CHF-59.25 Million CHF-59.01 Million CHF118.57 Million CHF-90.95 Million CHF-28.98 Million
Capital Expenditures CHF723.00K CHF575.00K CHF1.42 Million CHF1.31 Million CHF1.68 Million
Free Cash Flow CHF-59.97 Million CHF-59.81 Million CHF117.15 Million CHF-92.26 Million CHF-30.67 Million
Investing Cash Flow CHF40.49 Million CHF44.64 Million CHF-101.12 Million CHF-22.24 Million CHF-21.75 Million
Financing Cash Flow CHF14.43 Million CHF-1.17 Million CHF-1.57 Million CHF50.58 Million CHF113.20 Million
Dividends Paid CHF250.00K
Stock-Based Compensation CHF4.11 Million CHF5.21 Million CHF5.09 Million CHF4.08 Million CHF2.93 Million
Depreciation CHF2.37 Million CHF2.42 Million CHF2.39 Million CHF2.56 Million CHF2.89 Million
Change in Cash CHF-3.44 Million CHF-20.64 Million CHF16.13 Million CHF-61.91 Million CHF58.01 Million

Molecular Partners AG Earnings History — EPS Actual vs. Analyst Estimates

Track Molecular Partners AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Jun 03, 2026 0.00 -0.32 +100.00%
Mar 04, 2026 -0.31
Oct 30, 2025 -0.32 -0.39 +17.95%
Aug 25, 2025 -0.55 -0.37 -47.43%
May 15, 2025 -0.45 -0.37 -21.62%
Mar 06, 2025 -0.30 -0.56 +45.59%
Oct 31, 2024 -0.49 -0.54 +9.26%
Aug 26, 2024 -0.45